For their part, Chinese officials describe “the so-called Xinjiang issue” as a lie used to undermine the nation’s stability ...

Takeda Pharmaceutical Co. (TAK) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...

Takeda holds a 33.4% stake in the new company while Astellas and SMBC own 33.4% and 33.2% stakes, respectively.

Launched by UN Trade and Development (UNCTAD) on 23 April, the report entitled “Global economic fracturing and shifting investment patterns” examines the complex landscape of global foreign direct ...